EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. Guillermo, Jänne, Pasi A., Lee, Jeffrey C., Tracy, Sean, Greulich, Heidi, Gabriel, Stacey, Herman, Paula, Kaye, Frederic J. +9 more·2004·Science
DOI 10.1126/science.1099314

Cited by (1,066)

Items 101–200 of 1,066

  1. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
    Byers, Lauren Averett, Diao, Lixia, Wang, Jing, Saintigny, Pierre, Girard, Luc, Peyton, Michael, Shen, Li, Fan, Youhong, Giri, Uma, Tumula, Praveen K. et al. · 2013 · Clinical Cancer Research
  2. The quest to overcome resistance to EGFR-targeted therapies in cancer
    Curtis Robert Chong, Pasi Antero Janne · 2013 · Nature Medicine
  3. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
    Arteaga, Carlos L., Engelman, Jeffrey A. · 2014 · Cancer Cell
  4. Initial impact of the sequencing of the human genome
    Lander, Eric S. · 2011 · Nature
  5. The Next-Generation Sequencing Revolution and Its Impact on Genomics
    Daniel C. Koboldt, Karyn Meltz Steinberg, David E. Larson, Richard K. Wilson, Elaine R. Mardis · 2013 · Cell
  6. Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
    Scher, Howard I., Sawyers, Charles L. · 2005 · Journal of Clinical Oncology
  7. Lung cancer: Biology and treatment options
    Hassan Lemjabbar‐Alaoui, Omer Ul Hassan, Yiwei Yang, Petra C. Buchanan · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  8. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
    Skoulidis, Ferdinandos, Heymach, John V. · 2019 · Nature Reviews Cancer
  9. The ERBB network: at last, cancer therapy meets systems biology
    Yosef Yarden, Gur Pines · 2012 · Nature reviews. Cancer
  10. Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
    Nikhil Wagle, Caroline Emery, Michael F. Berger, Matthew J. Davis, Allison M. Sawyer, Panisa Pochanard, Sarah M. Kehoe, Cory M. Johannessen, Laura E. MacConaill, William C. Hahn et al. · 2011 · Journal of Clinical Oncology
  11. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
    Jussi Pekka Koivunen, Craig H. Mermel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison Holmes Tisch, Hwan Geun Choi, Jhingook Kim, Derek Y. Chiang, Roman Kurt Thomas et al. · 2008 · Clinical Cancer Research
  12. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A F · 2009 · Oncogene
  13. High-throughput oncogene mutation profiling in human cancer
    Roman Kurt Thomas, Alissa C. Baker, Ralph M. Debiasi, Wendy Winckler, Thomas LaFramboise, William M. Lin, Meng Wang, Whei Feng, Thomas Zander, Laura E. MacConaill et al. · 2007 · Nature Genetics
  14. Lung cancer in never smokers – A review
    S. Couraud, Gérard Zalcman, Bernard J. Milleron, Franck Morin, Pierre-Jean Souquet · 2012 · European Journal of Cancer
  15. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
    Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L et al. · 2011 · The Lancet
  16. ErbB receptors and signaling pathways in cancer
    Hynes, Nancy E, MacDonald, Gwen · 2009 · Current Opinion in Cell Biology
  17. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    Eunice Lee Kwak, Raffaella Sordella, Daphne W. Bell, Nadia Godin-Heymann, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, David R. Driscoll, Panos M. Fidias, Thomas James Lynch et al. · 2005 · Proceedings of the National Academy of Sciences
  18. EGFR Mutations and Lung Cancer
    Gilda da Cunha Santos, Frances A. Shepherd, Ming‐Sound Tsao · 2011 · Annual Review of Pathology Mechanisms of Disease
  19. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    Moroni, Mauro, Veronese, Silvio, Benvenuti, Silvia, Marrapese, Giovanna, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Gambacorta, Marcello, Siena, Salvatore, Bardelli, Alberto · 2005 · The Lancet Oncology
  20. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
    Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, Yasushi Yatabe · 2005 · Journal of Clinical Oncology
  21. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
    Yong Jia, Cai‐Hong Yun, Eunyoung Park, Dalia Ercan, Mari Manuia, Jose Juarez, Chunxiao Xu, Kevin Rhee, Ting Chen, Haikuo Zhang et al. · 2016 · Nature
  22. Current Challenges in Cancer Treatment
    Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2016 · Clinical Therapeutics
  23. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta, Dihua Yu, Mien‐Chie Hung, Gabriel N. Hortobágyi, Francisco J. Esteva · 2006 · Nature Clinical Practice Oncology
  24. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel et al. · 2009 · Journal of Clinical Oncology
  25. The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
    Scaltriti, Maurizio, Baselga, José · 2006 · Clinical Cancer Research
  26. Activating mutations in ALK provide a therapeutic target in neuroblastoma
    George, Rani E., Sanda, Takaomi, Hanna, Megan, Fröhling, Stefan, II, William Luther, Zhang, Jianming, Ahn, Yebin, Zhou, Wenjun, London, Wendy B., McGrady, Patrick et al. · 2008 · Nature
  27. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
    Paul Geeleher, Nancy Jean Cox, R. Stephanie Huang · 2014 · Genome biology
  28. The BATTLE Trial: Personalizing Therapy for Lung Cancer
    Edward S. Kim, Roy S. Herbst, Ignacio Ivan Wistuba, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, David J. Stewart, Marshall E. Hicks, Jeremy J. Erasmus, Sanjay Kumar Gupta et al. · 2011 · Cancer Discovery
  29. Awakening guardian angels: drugging the p53 pathway
    Brown, Christopher J., Lain, Sonia, Verma, Chandra S., Fersht, Alan R., Lane, David P. · 2009 · Nature Reviews Cancer
  30. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
    Ulrich Gatzemeier, Anna Pluzanska, Aleksandra Szczęsna, Eckhard Kaukel, Jaromı́r Roubec, Flavio De Rosa, Janusz Milanowski, Hanna Karnicka-Mlodkowski, Miloš Pešek, Piotr Serwatowski et al. · 2007 · Journal of Clinical Oncology
  31. Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Ron Bose, Shyam M. Kavuri, Adam C. Searleman, Wei Shen, Dong Shen, Daniel C. Koboldt, John D. Monsey, Nicholas J. Goel, Adam B. Aronson, Shunqiang Li et al. · 2012 · Cancer Discovery
  32. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
    Jonathan M. Weiss, Martin L. Sos, Danila Seidel, Martin Peifer, Thomas Zander, Johannes M. Heuckmann, Roland Tillmann Ullrich, Roopika Menon, Sebastian H. Maier, Alex Soltermann et al. · 2010 · Science Translational Medicine
  33. Advances in covalent drug discovery
    Boike, Lydia, Henning, Nathaniel J., Nomura, Daniel K. · 2022 · Nature Reviews Drug Discovery
  34. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen Frances Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris et al. · 2006 · Clinical Cancer Research
  35. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
    Gillette, Michael A., Satpathy, Shankha, Cao, Song, Dhanasekaran, Saravana M., Vasaikar, Suhas V., Krug, Karsten, Petralia, Francesca, Li, Yize, Liang, Wen-Wei, Reva, Boris et al. · 2020 · Cell
  36. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations
    Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona et al. · 2008 · Journal of Clinical Oncology
  37. Role of epidermal growth factor receptor in breast cancer
    Hiroko Masuda, Dongwei Zhang, Chandra Bartholomeusz, Hiroyoshi Doihara, Gabriel N. Hortobágyi, Naoto Tada Ueno · 2012 · Breast Cancer Research and Treatment
  38. Intragenic ERBB2 kinase mutations in tumours
    Stephens, Philip, Hunter, Chris, Bignell, Graham, Edkins, Sarah, Davies, Helen, Teague, Jon, Stevens, Claire, O'Meara, Sarah, Smith, Raffaella, Parker, Adrian et al. · 2004 · Nature
  39. Oncogenic PI3K deregulates transcription and translation
    Andreas G. Bader, Sohye Kang, Li Zhao, Peter K. Vogt · 2005 · Nature reviews. Cancer
  40. Comparing antibody and small-molecule therapies for cancer
    Kohzoh Imai, Akinori Takaoka · 2006 · Nature reviews. Cancer
  41. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman, David, Pao, William, Riely, Gregory J., Engelman, Jeffrey A., Kris, Mark G., Jänne, Pasi A., Lynch, Thomas, Johnson, Bruce E., Miller, Vincent A. · 2010 · Journal of Clinical Oncology
  42. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
    Shang‐Gin Wu, Jin‐Yuan Shih · 2018 · Molecular Cancer
  43. Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
    Oxnard, Geoffrey R., Paweletz, Cloud P., Kuang, Yanan, Mach, Stacy L., O'Connell, Allison, Messineo, Melissa M., Luke, Jason J., Butaney, Mohit, Kirschmeier, Paul, Jackman, David M. et al. · 2014 · Clinical Cancer Research
  44. EGF receptor trafficking: consequences for signaling and cancer
    Alejandra Tomás, Clare E. Futter, Emily R. Eden · 2013 · Trends in Cell Biology
  45. Identification of molecular apocrine breast tumours by microarray analysis
    Pierre J. Farmer, Herve R. Bonnefoi, Véronique Becette, Michele Tubiana-Hulin, P. Fumoleau, Denis Larsimont, Gaëtan Marie MacGrogan, Jonas C. S. Bergh, David Cameron, Darlene Goldstein et al. · 2005 · Oncogene
  46. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
    Christophe Massard, Stefan Michiels, Charles Ferté, Marie‐Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loïc Verlingue, Ecaterina E. Ileana, Silvia Rosellini, Samy Ammari et al. · 2017 · Cancer Discovery
  47. EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
    Antonio Marchetti, Carla Martella, Lara Felicioni, Fabio Barassi, Simona Salvatore, Antonio Chella, Pierpaolo Camplese, Teodorico Iarussi, Felice Mucilli, Andrea Mezzetti et al. · 2005 · Journal of Clinical Oncology
  48. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
    Lais Osmani, Frederic Barton Askin, Edward Gabrielson, Qing Kay Li · 2017 · Seminars in Cancer Biology
  49. EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
    Lynn T. Tanoue · 2006 · Yearbook of Pulmonary Disease
  50. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
    Westover, D., Zugazagoitia, J., Cho, B.C., Lovly, C.M., Paz-Ares, L. · 2018 · Annals of Oncology
  51. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
    Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang, Soohyun Jeong, Jeongmi Kim, In Sil Choi, Do‐Youn Oh, Jee Hyun Kim, Dong‐Wan Kim, Doo Hyun Chung et al. · 2005 · Journal of Clinical Oncology
  52. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
    Bardelli, Alberto, Siena, Salvatore · 2010 · Journal of Clinical Oncology
  53. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
    Shailaja Kalyankrishna, Jennifer Rubin Grandis · 2006 · Journal of Clinical Oncology
  54. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    Linardou, Helena, Dahabreh, Issa J, Kanaloupiti, Dimitra, Siannis, Fotios, Bafaloukos, Dimitrios, Kosmidis, Paris, Papadimitriou, Christos A, Murray, Samuel · 2008 · The Lancet Oncology
  55. Non–Small Cell Lung Cancer
    _ _ · 2008 · Journal of the National Comprehensive Cancer Network
  56. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    Han, Ji-Youn, Park, Keunchil, Kim, Sang-We, Lee, Dae Ho, Kim, Hyae Young, Kim, Heung Tae, Ahn, Myung Ju, Yun, Tak, Ahn, Jin Seok, Suh, Cheolwon et al. · 2012 · Journal of Clinical Oncology
  57. Nanomedicine therapeutic approaches to overcome cancer drug resistance
    Markman, Janet L., Rekechenetskiy, Arthur, Holler, Eggehard, Ljubimova, Julia Y. · 2013 · Advanced Drug Delivery Reviews
  58. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib
    Engelman, Jeffrey A., Zejnullahu, Kreshnik, Gale, Christopher-Michael, Lifshits, Eugene, Gonzales, Andrea J., Shimamura, Takeshi, Zhao, Feng, Vincent, Patrick W., Naumov, George N., Bradner, James E. et al. · 2007 · Cancer Research
  59. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    Gregory J. Riely, William J. Pao, DuyKhanh P. Ceppa, Allan R. Li, Naiyer A. Rizvi, Ennapadam S. Venkatraman, Maureen Frances Zakowski, Mark G. Kris, Marc Ladanyi, Vincent A. Miller · 2006 · Clinical Cancer Research
  60. Non–Small Cell Lung Cancer
    David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas Anthony D’Amico, Todd L. Demmy, Apar Kishor Ganti et al. · 2010 · Journal of the National Comprehensive Cancer Network
  61. Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
    Martin Reck, Klaus Friedrich Rabe · 2017 · New England Journal of Medicine
  62. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
    Jose M Baselga, Carlos L. Arteaga · 2005 · Journal of Clinical Oncology
  63. Molecular basis for sunitinib efficacy and future clinical development
    Sandrine J. Faivre, George D. Demetri, William Sargent, Éric Raymond · 2007 · Nature Reviews Drug Discovery
  64. EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
    Yamashita, Taro, Forgues, Marshonna, Wang, Wei, Kim, Jin Woo, Ye, Qinghai, Jia, Huliang, Budhu, Anuradha, Zanetti, Krista A., Chen, Yidong, Qin, Lun-Xiu et al. · 2008 · Cancer Research
  65. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
    2015 · Europe PMC (PubMed Central)
  66. Management of non-small-cell lung cancer: recent developments
    Martin Reck, David Felix Heigener, Tony S.K. Mok, Jean‐Charles Soria, Klaus Friedrich Rabe · 2013 · The Lancet
  67. <i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation
    Takezawa, Ken, Pirazzoli, Valentina, Arcila, Maria E., Nebhan, Caroline A., Song, Xiaoling, de Stanchina, Elisa, Ohashi, Kadoaki, Janjigian, Yelena Y., Spitzler, Paula J., Melnick, Mary Ann et al. · 2012 · Cancer Discovery
  68. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
    Jeffrey A. Engelman, Pasi Antero Janne · 2008 · Clinical Cancer Research
  69. Lung Cancer in Never Smokers: A Review
    Janakiraman Subramanian, Ramaswamy Govindan · 2007 · Journal of Clinical Oncology
  70. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Hirsch, Fred R., Varella-Garcia, Marileila, Bunn, Paul A., Franklin, Wilbur A., Dziadziuszko, Rafal, Thatcher, Nick, Chang, Alex, Parikh, Purvish, Pereira, José Rodrigues, Ciuleanu, Tudor et al. · 2006 · Journal of Clinical Oncology
  71. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C. Heng, Suzanne Eleanor Dahlberg, Pasi Antero Janne, Suman Verma et al. · 2016 · Journal of Clinical Oncology
  72. Epidermal Growth Factor Receptor Targeting in Cancer
    John M. Mendelsohn, Jose M Baselga · 2006 · Seminars in Oncology
  73. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
    Paul K. Paik, Maria E. Arcila, Michael G. Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely · 2011 · Journal of Clinical Oncology
  74. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
    Toshimi Takano, Yuichiro Ohe, Hiromi Sakamoto, Koji Tsuta, Yoshihiro Matsuno, Ukihide Tateishi, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine et al. · 2005 · Journal of Clinical Oncology
  75. Exploring the Genomes of Cancer Cells: Progress and Promise
    Michael R. Stratton · 2011 · Science
  76. Understanding resistance to EGFR inhibitors—impact on future treatment strategies
    Wheeler, Deric L., Dunn, Emily F., Harari, Paul M. · 2010 · Nature Reviews Clinical Oncology
  77. Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas
    Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi et al. · 2005 · Cancer Research
  78. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
    Min Yuan, Lili Huang, Jianhua Chen, Jie Wu, Qing Xu · 2019 · Signal Transduction and Targeted Therapy
  79. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
    Greulich, Heidi, Chen, Tzu-Hsiu, Feng, Whei, Jänne, Pasi A, Alvarez, James V, Zappaterra, Mauro, Bulmer, Sara E, Frank, David A, Hahn, William C, Sellers, William R et al. · 2005 · PLoS Medicine
  80. Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
    Scott J. Rodig, Mari A. Mino-Kenudson, Sanja Đačić, Beow Yong Yeap, Alice Tsang Shaw, Justine A. Barletta, Hannah Stubbs, Kenny Law, Neal Ian Lindeman, Eugene Jerome Mark et al. · 2009 · Clinical Cancer Research
  81. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
    Nasser H. Hanna, Paul A. Bunn, Corey Jay Langer, Lawrence H. Einhorn, Troy H. Guthrie, Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark E. Morrison et al. · 2006 · Journal of Clinical Oncology
  82. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
    Day, Chi-Ping, Merlino, Glenn, Van Dyke, Terry · 2015 · Cell
  83. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
    Gary J. Kelloff, John M. Hoffman, Bruce Evan Johnson, Howard I. Scher, Barry Alan Siegel, Edward Y. Cheng, Bruce D. Cheson, Joyce O’Shaughnessy, Kathryn Z. Guyton, David A. Mankoff et al. · 2005 · Clinical Cancer Research
  84. Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations
    Margaret C. Thompson, Christine E. Fuller, Twala L. Hogg, James Dalton, David Finkelstein, Ching C. Lau, Murali Chintagumpala, Adekunle M. Adesina, David M. Ashley, Stewart J. Kellie et al. · 2006 · Journal of Clinical Oncology
  85. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    Gao, Sizhi Paul, Mark, Kevin G., Leslie, Kenneth, Pao, William, Motoi, Noriko, Gerald, William L., Travis, William D., Bornmann, William, Veach, Darren, Clarkson, Bayard et al. · 2007 · Journal of Clinical Investigation
  86. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
    Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee et al. · 2021 · Journal of Clinical Oncology
  87. The cell cycle and cancer
    Gareth Haydn Williams, Kai Stoeber · 2011 · The Journal of Pathology
  88. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
    Hisayuki Shigematsu, Adi F. Gazdar · 2005 · International Journal of Cancer
  89. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David Matthew Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich et al. · 2016 · Nature Communications
  90. Mitochondrial metabolism promotes adaptation to proteotoxic stress
    Tsvetkov, Peter, Detappe, Alexandre, Cai, Kai, Keys, Heather R., Brune, Zarina, Ying, Weiwen, Thiru, Prathapan, Reidy, Mairead, Kugener, Guillaume, Rossen, Jordan et al. · 2019 · Nature Chemical Biology
  91. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    Yano, Seiji, Wang, Wei, Li, Qi, Matsumoto, Kunio, Sakurama, Haruko, Nakamura, Takahiro, Ogino, Hirokazu, Kakiuchi, Soji, Hanibuchi, Masaki, Nishioka, Yasuhiko et al. · 2008 · Cancer Research
  92. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith William Pratz, Gabriel Pallares, Qi Chao et al. · 2009 · Blood
  93. Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers
    Dogan, Snjezana, Shen, Ronglai, Ang, Daphne C., Johnson, Melissa L., D'Angelo, Sandra P., Paik, Paul K., Brzostowski, Edyta B., Riely, Gregory J., Kris, Mark G., Zakowski, Maureen F. et al. · 2012 · Clinical Cancer Research
  94. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
    William J. Pao, Vincent A. Miller · 2005 · Journal of Clinical Oncology
  95. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
    Peter T. Harrison, Simon Vyse, Paul H. Huang · 2019 · Seminars in Cancer Biology
  96. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
    Hata, Aaron N., Engelman, Jeffrey A., Faber, Anthony C. · 2015 · Cancer Discovery
  97. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    Josep Maria Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn · 2015 · Nature Reviews Clinical Oncology
  98. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Daphne W. Bell, Thomas James Lynch, Daniel A. Haber · 2007 · Journal of Clinical Oncology
  99. c-Src and cooperating partners in human cancer
    Ishizawar, Rumey, Parsons, Sarah J. · 2004 · Cancer Cell
  100. Small molecules, big impact: 20 years of targeted therapy in oncology
    Philippe Lucien Bedard, David Michael Hyman, Matthew Steven Davids, Lillian L. Siu · 2020 · The Lancet